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Background: The impact of ST-segment elevation myocardial infarction (STEMI) on neointimal hyperplasia (NIH) after primary stenting has not 
been studied in detail.
methods: From formal core laboratory based intravascular ultrasound (IVUS) substudies, we compared the vascular responses after paclitaxel-
eluting stents (PES) and bare metal stents (BMS) in STEMI pts from the HORIZONS-AMI trial to non-MI pts from the TAXUS IV, V, and ATLAS Trials.
results: Compared to non-MI pts (n=857), STEMI pts (n=224) were younger (58.8±11.3 vs 61.9±10.7 yrs, p=0.0001) and less often diabetic 
(14.3% vs 25.2%, p=0.0005), hyperlipidemic (41.5% vs 75.5%, p<0.0001), or with a history of a prior MI (6.3% vs 28.8%, p<0.0001). Though 
minimum lumen area (MLA) post procedure was similar, %NIH at the MLA site and net volume obstruction (=neointimal volume/stent volume*100) 
in both PES and BMS were significantly less in STEMI than on-MI pts, resulting in a significantly larger MLA at follow-up (Table). Multivariate 
linear regression analysis showed that STEMI (coefficient -0.20, p<0.001), DES use (coefficient -0.50, p<0.0001), stent length (coefficient 0.075, 
p=0.0055), and diabetes (coefficient 0.053, p=0.049) were the independent predictors for net volume obstruction.
conclusion: Implantation of PES and BMS in pts with STEMI compared to non-MI was associated with less NIH. 
Table
PES
p-value
BMS
p-value
STEMI non-MI STEMI non-MI
Post-procedure, n n=178 n=517 n=60 n=158
MLA, mm2 6.6 (5.2, 7.9) 6.0 (4.9, 7.7) 0.11 6.5 (5.3, 8.1) 6.8 (5.0, 8.6) 0.96
Follow-up, n n=191 n=642 n=65 n=215
Stent length, mm 24.6 (19.5, 33.4) 23.0 (17.0, 32.0) 0.009 21.6 (17.8, 27.9) 21.9 (17.0, 32.0) 0.82
MLA, mm2 5.8 (4.3, 7.6) 4.8 (3.5, 6.4) <0.0001 5.3 (3.7, 6.7) 3.7 (2.5, 5.4) <0.0001
NIH at the MLA site, mm2 1.2 (0.0, 2.6) 1.6 (0.6, 2.8) 0.01 2.4 (1.3, 3.7) 2.9 (2.0, 4.3) 0.03
% NIH at the MLA site, % 17.7 (0.0 30.9) 24.0 (10.4, 41.6) 0.0002 31.6 (17.5, 48.4) 43.8 (31.9, 55.7) 0.0003
Net volume obstruction, % 6.5 (2.2, 10.8) 10.8 (4.3, 20.0) <0.0001 15.6 (7.2, 28.8) 30.4 (21.5, 39.5) <0.0001
